RECRUITING

Responses to Genetic Risk Modifier Testing Among Women with BRCA1/2 Mutations

Description

The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.

Conditions

Genetic TestingBRCA1/2
Talk to us

Related Conditions:

Genetic TestingBRCA1/2

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.

Responses to Genetic Risk Modifier Testing Among Women with BRCA1/2 Mutations

Responses to Genetic Risk Modifier Testing Among Women with BRCA1/2 Mutations

Condition
Genetic Testing
Intervention / Treatment

-

Contacts and Locations

Boston

Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts, United States, 02115

Basking Ridge

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States, 07920

Commack

Memorial Sloan Kettering Commack, Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau, Uniondale, New York, United States, 11553

Philadelphia

Abramson Cancer Center at University of Pennsylvania Medical Center (Data Collection Only), Philadelphia, Pennsylvania, United States, 19104-4283

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female patient, age 25 years or older (given that women under this age are not generally recommended to receive BRCA1/2 genetic testing)
  • * Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified
  • * No personal history of breast cancer
  • * English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
  • * Previous receipt of any prophylactic mastectomy.
  • * Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.
  • * Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.

Ages Eligible for Study

25 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Jada Hamilton, PhD, MPH, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2025-01